Takeda director reports 795 ADS holdings

Takeda Pharmaceutical Co. Ltd. director Bruce D. Broussard filed an initial Form 3 reporting his holdings in the company.

Accepted by SEC EDGAR 07/06/2026 - 11:31 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Takeda Pharmaceutical Co. Ltd. director Bruce D. Broussard filed an initial Form 3 reporting his holdings in the company. The filing shows he directly owns 795 American Depositary Shares as of the reported date. This is a baseline disclosure of his beneficial ownership rather than a new buy or sell transaction.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider BROUSSARD BRUCE D

Role Director

Type	Security	Shares	Price	Value
Holding	American Depositary Shares	--	--	--

Holdings: American Depositary Shares — 795 shares (Direct)

Key Figures

ADS holdings: 795 American Depositary Shares Form type: Form 3 Reporting role: Director

3 metrics

ADS holdings 795 American Depositary Shares Direct ownership following reported entry

Form type Form 3 Initial statement of beneficial ownership

Reporting role Director Status of Bruce D. Broussard at issuer

Key Terms

American Depositary Shares, Form 3, beneficial ownership

3 terms

American Depositary Shares financial

"security_title: "American Depositary Shares""

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

Form 3 regulatory

"INSIDER FILING DATA (Form 3)"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

beneficial ownership regulatory

"initial statement of beneficial ownership by a reporting insider"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Bruce D. Broussard’s Form 3 for TAKEDA PHARMACEUTICAL CO LTD show?

The Form 3 shows Bruce D. Broussard, a director of Takeda, directly owns 795 American Depositary Shares. This is an initial beneficial ownership report, establishing his starting position rather than indicating a new purchase or sale.

Did Bruce D. Broussard buy or sell Takeda (TAK) shares in this Form 3?

The filing does not report any buy or sell transaction; it records holdings only. It lists a direct position of 795 American Depositary Shares, serving as a baseline ownership disclosure required when becoming a reporting insider.

How many Takeda American Depositary Shares does Bruce D. Broussard hold?

He is reported as directly holding 795 American Depositary Shares following the reported entry. This figure in the Form 3 represents his beneficial ownership position at that time, not a change from a prior transaction in this document.

What type of security is reported in Bruce D. Broussard’s Takeda Form 3?

The security reported is American Depositary Shares of Takeda Pharmaceutical Co. Ltd. The Form 3 indicates direct ownership of 795 of these ADS, which are a way for investors to hold interests in a non-U.S. company’s shares.

Does the Takeda Form 3 for Bruce D. Broussard include any derivative securities?

The Form 3 data provided shows no derivative securities for Bruce D. Broussard. Only 795 American Depositary Shares are listed as directly owned, and the derivative securities section is empty in this filing snapshot.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

BROUSSARD BRUCE D

(Last) (First) (Middle)

C/O HP INC.

1501 PAGE MILL ROAD

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/24/2026

3. Issuer Name and Ticker or Trading Symbol
TAKEDA PHARMACEUTICAL CO LTD [ TAK ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
American Depositary Shares	795	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Kate Huleatt, by power of attorney, for Bruce Broussard	07/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)